跳至主要内容
临床试验/NCT02215174
NCT02215174终止1 期

Rosuvastatin Pharmacokinetic (PK) Study in Caucasian and Asian Morbid Obese Patients

University of California, San Francisco2 个研究点 分布在 2 个国家目标入组 21 人开始时间: 2015年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
21
试验地点
2
主要终点
Area-under-the-concentration curve (AUC) of rosuvastatin

研究概览

简要总结

Statins are the first-line and most commonly prescribed drugs for the prevention of cardiovascular diseases and stroke in the world. Our preliminary studies suggest that Caucasians might have a higher risk of developing potentially life-threatening drug-drug interactions than Asians when taking statins. Drug-drug interactions occur in the body when two or more drugs interact in a way that alters their effectiveness and/or toxicity. These interactions are becoming an increasingly severe problem with statin usage since patients at higher risk for cardiovascular diseases also take statins combined with many other drugs, such as antihypertensive and diabetic drugs. Our study is aimed at understanding the molecular factors and providing a sound basis for the interethnic dosage and response differences for statins.

Drug-transporting proteins in intestine and liver tissues are responsible for taking up statins into the blood. It is hypothesized that there are interethnic function differences of these proteins and that they account for differences in statin blood levels between Caucasians and Asians and the frequency and/or severity of their respective drug-drug interactions. A clinical study will be conducted with Caucasian and Asian subjects undergoing gastric bypass surgery so excess intestine and liver tissue can be acquired as part of the standard procedure. Protein levels will be quantified in the tissues and correlate them with different statin blood levels.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects that are scheduled for bariatric surgery.
  • Subjects that are able and willing to donate surplus intestinal tissue.
  • Subjects with solute carrier organic anion transporter *1 (SLCO1B1) and breast cancer resistant protein (BCRP) 421CC genotypes.
  • White/Caucasian/European and Asian/East Asian heritage individuals, male or female, 18 years of age or older.
  • BMI between 30-55 kg/m2
  • Be able to read, speak, and understand English(UCSF) and Chinese(Taiwan).
  • Subjects capable of providing informed consent and completing the requirements of the study.

排除标准

  • Subjects with active liver and kidney problems, severe cardiovascular diseases, type I diabetes, advanced pulmonary disease, and cancers.
  • Subjects on chronic prescription or over the counter medication that have previously been reported to exhibit drug-drug interactions with rosuvastatin and cannot be stopped two weeks prior to and during the study, including gemfibrozil, cyclosporine, atazanavir, lopinavir and ritonavir.
  • Subjects incapable of multiple blood draws (HCT < 30mg/dL).
  • Subjects with a history of rhabdomyolysis.
  • Subjects with a history of drug-related myalgias.
  • Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias.
  • Subjects with a history of GI bleed or peptic ulcer disease.
  • Subjects with a recent history of trauma.
  • Subjects who smoke tobacco or have ongoing alcohol or illegal drug use.
  • Subjects who are pregnant, lactating, or trying to conceive during the study period.
  • Subjects allergic to rosuvastatin or any known component of the medications.

研究组 & 干预措施

Asians

Experimental

Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor

干预措施: Rosuvastatin (Drug)

Caucasians

Experimental

Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor

干预措施: Rosuvastatin (Drug)

结局指标

主要结局

Area-under-the-concentration curve (AUC) of rosuvastatin

时间窗: 0,1,2,3,4,5,6,8,12,24,36,48 hr post dosing

次要结局

  • Change in oral clearance of rosuvastatin(Pre-surgery period: 48 hr after dosing; post-surgery period: 48 hr after dosing. Two periods separated by at least two months.)
  • Descriptive comparison of messenger ribonucleic acid (mRNA) and protein expression in the tissues(Day of the surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验